Pourmand G, Ramezani R, Sabahgoulian B, Nadali F, Mehrsai Ar, Nikoobakht Mr, Allameh F, Hossieni Sh, Seraji A, Rezai M, Haidari F, Dehghani S, Razmandeh R, Pourmand B
Urology Research Center, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Iran J Public Health. 2012;41(2):47-52. Epub 2012 Feb 29.
To determine a cut-off point of tPSA and PSAD to prevent unnecessary invasive cancer-diagnosing tests in the community.
This study was performed on 688 consecutive patients referred to our center due to prostatism, suspicious lesions on digital rectal examination and/or elevated serum PSA levels. All patients underwent transrectal ultrasound guided biopsies and obtained PSAD. Serum levels of tPSA and fPSA were measured by chemiluminescence. Comparisons were done using tests of accuracy (AUC-ROC).
Prostate cancer was detected in 334 patients, whereas the other 354 patients were suffering from benign prostate diseases. The mean tPSA in case and control groups were 28.32±63.62 ng/ml and 7.14±10.04 ng/ml; the mean f/tPSA ratios were 0.13± 0.21 and 0.26±0.24 in PCa and benign prostate disease groups; the mean PSAD rates were 0.69±2.24, 0.12±0.11, respectively. Statistically significant differences were found (P <0.05). Using ROC curve analysis, it was revealed that AUC was 0.78 for tPSA and 0.80 for f/tPSA. Sensitivity was 71% for the cut-off value of 7.85ng/ml. For f/tPSA ratio, the optimal cut-off value was 0.13 which produced the sensitivity of 81.4% and for PSAD, it was15%.
As this trial is different from the European and American values, we should be more cautious in dealing with the prostate cancer upon the obtained sensitivity and specificity for PCa diagnosis (7.85ng/mL for tPSA, 15% for PSAD and 0.13 for f/tPSA ratio).
确定总前列腺特异抗原(tPSA)和前列腺特异抗原密度(PSAD)的截断点,以避免社区中不必要的侵入性癌症诊断检测。
本研究对688例因前列腺增生、直肠指检可疑病变和/或血清PSA水平升高而转诊至本中心的连续患者进行。所有患者均接受经直肠超声引导下活检并获得PSAD。采用化学发光法测定血清tPSA和游离前列腺特异抗原(fPSA)水平。使用准确性检验(AUC-ROC)进行比较。
334例患者检测出前列腺癌,其余354例患者患有良性前列腺疾病。病例组和对照组的平均tPSA分别为28.32±63.62 ng/ml和7.14±10.04 ng/ml;前列腺癌组和良性前列腺疾病组的平均f/tPSA比值分别为0.13±0.21和0.26±0.24;平均PSAD率分别为0.69±2.24、0.12±0.11。差异有统计学意义(P<0.05)。通过ROC曲线分析发现,tPSA的AUC为0.78,f/tPSA的AUC为0.80。截断值为7.85 ng/ml时,敏感性为71%。对于f/tPSA比值,最佳截断值为0.13,敏感性为81.4%,对于PSAD,截断值为15%。
由于本试验结果与欧美值不同,基于所获得的前列腺癌诊断敏感性和特异性(tPSA为7.85 ng/mL,PSAD为15%,f/tPSA比值为0.13),我们在处理前列腺癌时应更加谨慎。